Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.
Wouters M, Dijkgraaf EM, Kuijjer ML, Jordanova ES, Hollema H, Welters M, van der Hoeven J, Daemen T, Kroep JR, Nijman HW, van der Burg SH. Wouters M, et al. Among authors: dijkgraaf em. Oncoimmunology. 2015 Jan 7;3(12):e962397. doi: 10.4161/21624011.2014.962397. eCollection 2014 Dec. Oncoimmunology. 2015. PMID: 25964862 Free PMC article.
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR. Dijkgraaf EM, et al. Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216383 Free article. Clinical Trial.
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.
Santegoets SJAM, de Groot AF, Dijkgraaf EM, Simões AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH. Santegoets SJAM, et al. Among authors: dijkgraaf em. Oncoimmunology. 2018 May 31;7(8):e1465166. doi: 10.1080/2162402X.2018.1465166. eCollection 2018. Oncoimmunology. 2018. PMID: 30221063 Free PMC article.
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH. Dijkgraaf EM, et al. Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772. Oncotarget. 2015. PMID: 26334096 Free PMC article. Clinical Trial.
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH. Santegoets SJ, et al. Among authors: dijkgraaf em. Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28. Cancer Immunol Immunother. 2015. PMID: 26122357 Free PMC article.
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, van Bochove A, van Laarhoven HW, Meershoek-Klein Kranenbarg E, van Leeuwen-Stok AE, van de Velde CJ, Putter H, Nortier JW, van der Hoeven JJ, Pijl H, Kroep JR. de Groot S, et al. Among authors: dijkgraaf em. Breast Cancer Res Treat. 2015 Jan;149(2):461-6. doi: 10.1007/s10549-014-3256-4. Epub 2015 Jan 4. Breast Cancer Res Treat. 2015. PMID: 25556355 Free PMC article. Clinical Trial.